Navarro-Triviño, Francisco JLlamas-Molina, Jose MariaAyen-Rodriguez, AngelaCancela-Díez, BarbaraRuiz-Villaverde, Ricardo2025-01-072025-01-072020-09-122047-9956https://hdl.handle.net/10668/26066A 70-year-old man with a history of hypertension was evaluated in our dermatology department due to the appearance of a clinical picture compatible with bullous pemphigoid that was confirmed histologically. The lack of response to topical and systemic immunosuppressive treatment resulted in omalizumab being prescribed in a multidisciplinary committee based on the clinical and analytical findings and the patient's refusal to be treated with rituximab. The evaluation at 3 months showed the absence of blisters on the clinical examination. No associated adverse effects were observed. In the following 3 months the patient was administered medication at home in the absence of an anaphylactic reaction and with prior training by the nursing staff of the Hospital Pharmacy Service. After 6 months the medication was suspended with no relapses for 6 months since the last dose. Omalizumab, an anti-IgE monoclonal drug which has a good safety profile with minimum adverse side effects should be considered when there is a contraindication to the use of intravenous therapies (eg, immunoglobulins, rituximab) or prolonged immunosuppressive treatment (eg, methotrexate, azathioprine).enallergy and immunologyclinical medicinedermatologysafetysocial medicineAgedHumansImmunosuppressive AgentsMaleOmalizumabPemphigoid, BullousRituximabresearch article32920533open access10.1136/ejhpharm-2020-002418PMC8552126https://ejhp.bmj.com/content/ejhpharm/28/6/350.full.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8552126/pdf